ACM
CLRB icon

ADAR1 Capital Management’s Cellectar Biosciences CLRB Stock Holding History

ADAR1 Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,341
Closed -$12.7K – 216
2025
Q1 		$12.7K Sell
1,341
-18,168
-93% -$165K ﹤0.01% 195
2024
Q4 		$175K Sell
19,509
-14,563
-43% -$673K 0.04% 161
2024
Q3 		$2.19M Buy
34,072
+11,336
+50% +$748K 0.36% 47
2024
Q2 		$1.71M Buy
22,736
+1,318
+6% +$126K 0.32% 46
2024
Q1 		$2.56M Sell
21,418
-24,518
-53% -$2.66M 0.58% 35
2023
Q4 		$3.82M Buy
+45,936
New +$3.42M 1.36% 18

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

ADAR1 Capital Management's CLRB Position: Q2 2025 in Review

ADAR1 Capital Management sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 1,341 shares — an estimated $12.7K sold.

ADAR1 Capital Management first reported a position in CLRB in Q4 2023 and held it in 6 quarters. The position peaked at $3.82M in Q4 2023. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • ADAR1 Capital Management reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 1,341 Cellectar Biosciences shares in Q2 2025, an estimated $12.7K.
  • ADAR1 Capital Management first reported a position in Cellectar Biosciences in Q4 2023 and held it in 6 quarters.
  • ADAR1 Capital Management's Cellectar Biosciences position peaked at $3.82M in Q4 2023.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.